Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection

Comparative Study between Triple Therapy (Peginterferon /Ribavirin/Sofosbuvir) and Dual Therapy (Simeprevir /Sofosbuvir) in Treatment of Chronic HCV Patients

“…In triple therapy group, Leucopenia in this study was detected before treatment in 6.8% versus 49.6% of cases at the end of treatment which comes in disagreement with Wehmeyer and other colleagues [11] who revealed that leucopenia was occurred in 12.5% of cases.…”

Pegylated Interferon, Ribavirin, and Sofosbuvir Combination versus Pegylated Interferon, Ribavirin in the Management of Chronic Hepatitis C Egyptian Patients

“…Only 28 treatment-naïve patients with HCV genotype 4 infections were enrolled. The SVR frequency among this subgroup was 96.4% which is obviously greater than our reported frequency of 66.67%, also our study largely differs from result of Wehmeyer et al 27 , which report that patients receiving SOF/IFN/RBV achieve 100% SVR which reflects that data obtained from clinical trials are not always reproducible in real clinical settings. Most important explanation of difference in result between our study (IRS group) and studies of both Lawitz et al and Wehmeyer et al that we study on large number of patient (N=105), on other hand they study on 28, 24 respectively.…”

“…Research Article / JAPR ISSN: 2357-0539 (Online) Ebid et al, 2017, 1 (1), [25][26][27][28][29][30][31][32][33] …”

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

“…In small cohorts of HCV genotype 4 patients, sofosbuvir in combination with Peg‐IFN‐α and RBV has resulted in rates of sustained virological response (SVR) of 82%‐96% . In a real‐life cohort study, triple therapy with sofosbuvir plus Peg‐IFN‐α and RBV resulted in SVR in 10 of 12 (83%) HCV genotype 4 patients with severe fibrosis or compensated cirrhosis (Metavir F3‐F4) . The all‐oral combination of sofosbuvir plus RBV has shown SVR rates of 68%‐77% with 12 weeks of treatment and 90%‐93% with 24 weeks in HCV genotype 4 patients .…”

“…(10,11) In a real-life cohort study, triple therapy with sofosbuvir plus Peg-IFN-a and RBV resulted in SVR in 10 of 12 (83%) HCV genotype 4 patients with severe fibrosis or compensated cirrhosis (Metavir F3-F4). (12) The all-oral combination of sofosbuvir plus RBV has shown SVR rates of 68%-77% with 12 weeks of treatment and 90%-93% with 24 weeks in HCV genotype 4 patients. (13,14) Combining sofosbuvir with another directly acting antiviral DAA could have the advantages of even higher success rates and relatively short durations.…”